Trial Profile
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Evinacumab (Primary) ; Alirocumab
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Sponsors Regeneron Pharmaceuticals
- 13 Nov 2023 Results (n=14 from NCT04233918 and n=14 from NCT03409744) assessing Effects of Evinacumab on Atherogenic Lipoproteins in Children and Adolescents From Ages 5 to 17 Years With Homozygous Familial Hypercholesterolemia presented at the American Heart Association Scientific Sessions 2023
- 01 May 2023 Status changed from active, no longer recruiting to completed.
- 09 Nov 2022 Planned End Date changed from 25 Jan 2023 to 31 May 2023.